Look at their financials, they poured in tons of cash to generate the modest increase in sales. they must think investors are even bigger idiots than they actually are. The funny thing is they may be right.

how much money do they burn to generate that revenue?

Piper Jaffray report following Q3 2011 earnings:

Fluidigm reported 3Q11 revenue in-line with consensus, but better-than-expected loss per share. Product revenue grew 42.2% yoy to $10.6M, with both instruments (+29.4%) and consumables (+71.4%) contributing to the solid quarterly results.

Despite the unfavorable economic and budgetary pressures facing the life science tools industry, management described strong demand across product lines and geographies. Management increased F2011 guidance and now anticipates product revenue growth of 31%-33% (was 27%-30%) to $39.8M-$40.4M (was $38.6M- $39.5M).

We reiterate our Overweight rating on FLDM shares.

Piper Jaffray downgrades Fluidigm today.

Piper Jaffray report:
Management is frequently confident about their business (eg, multiple upward guidance revisions), but we were impressed with sensible reflection on the business, the challenges and their ability to focus on what is most important to them (operating success and managing growth) rather than be distracted by the market's laser-like focus on NIH/the Supercommittee. We continue to believe Fluidigm offers one of the more attractive growth stories in our coverage.

hard to justify at that price

Stock price just sunk below $13. Seems like a bargain as it'll likely rebound in the next few weeks.

Rising up !

how low will it go? current share holders must be upset.

If ABI/Life is doing a deal like that then maybe Fluidigm has something of real value. This is getting interesting!

Fluidigm and Life Technologies Cross-License a Broad Set of Intellectual Properties

Fluidigm Corporation (NASDAQ:FLDM) today announced that it has entered into a set of cross-licensing and sub-licensing agreements on a range of intellectual properties with Life Technologies (NASDAQ:LIFE).

Under the terms of the agreements, Fluidigm will gain broad access to patent families covering PCR related technologies of Life Technologies. In addition, Life Technologies will gain broad access to a number of Fluidigm patent families related to imaging readers and other technologies.

Keep Dreaming. No breakthrough products and still unable to purchase those reusable products. Revenue stream is drying up.

Fluidigm tops this list.

Seeking Alpha: Top 30 Rallying Small Cap Stocks With Significant Institutional Buying

The following is a list of stocks in rally mode, i.e. trading above their 20-day, 50-day and 200-day moving averages.
Furthermore, these stocks are small caps (market caps between $300M and $2B) and have experienced significant levels of institutional buying over the current quarter.
This list might offer an interesting starting point for momentum investors looking to follow trends set by big money managers.

Do you think these names will continue to rally? Use the list below as a starting point for your own analysis.

1. Fluidigm Corporation (FLDM): Scientific & Technical Instruments Industry. Market cap of $331.10M. Net institutional shares purchased over the current quarter equivalent to 60.06% of the company's 16.15M share float. The stock is currently 16.54% above its 20-day MA, 11.15% above its 50-day MA, and 11.73% above its 200-day MA. The stock has had a couple of great days, gaining 18.01% over the last week.

http://seekingalpha.com/article/277190-top-30-rallying-small-cap-stocks-...

This technology still has a fantastic potential other companies can only dream off!

$13.73, how low will it go?

soon to be a $5 stock.

Current stockholders will bail once lockout window expires. Watch for price Drop!

does not even compensate for the fall of the $ over the last years ;-(

Just saw that GW gave himself a 10% pay raise and the execs are in line for 50% bonuses. Pretty unseemly given the organization has never turned a profit in over a decade.

Performance of VP NA sales was very good but FW wants to hire his buds from his last job. FW is the greatest danger to Fluidigm's future.

She's still listed on their website but never was that stellar ... except at self-promotion (par for the course for an ex-ABI'er).

Notice recent FLDM SEC filings - some of the execs are rewarding themselves nicely - not clear the reason other than greed.

Stock price has fallen a bit recently.

It is true that she is no longer at Fluidigm. There is no way that she was a poor performer. Who ever wrote that is envious of her considerable abilities.

pushed out. history of poor performance.

Sad. I hope this rumor is false. Maybe the VP needs time out. No way was VP pushed out.

Ax fell today. Vp of NA sales pushed out.

north american sales are way down.

Rumor has it they are getting rid of their commercial lead in the States. Sales must not be where they need they to be.

I hope it goes up!

Does anybody have any comments on their stock price?

still a bad investment

Still no profit but they're moving in the right direction. Getting rid of that Singaporean BOD member was clearly a good move too. Could it be that GW is finally showing signs of a leadership backbone?

Fluidigm must now show a profit.

So when is this earning repport due? Is Fluidigm passing the profitability threshold anytime soon?

Short position on FLDM shares before earnings report

That's a homerun baby!

Nice, high-quality discourse here ...

Suck it

bad investment.

Well it's done now!

Don't, but years of following microfluidics. Fluidigm is supposely going public next week, that should be quite interesting to follow.

Who do work for at Fluidigm?

shrinking dimensions is not enough, this is not enabling. Without the purchase of Zymark (not really microfluidic) Caliper would have had the same ending as Aclara.

Only microfluidics company with enabling technology? what a joke, how about Caliper? You guys burned tons of money, generated a miserable revenue.

Compared to any other microfluidic company, Fluidigm is the only one having enabling technologies. Sure it is not perfect but no technology is, otherwise we’d stop bringing news ones to the market. The Digital array is truly unique, it allows to gain information that would not be accessible with current systems. Fluidigm has a fantastic potential in the diagnostic field, MRSA detection is basically straight forward. Can’t wait to read more on the topic.

Days are definitely number for this company. An IPO will for sure be less than eventful for investors in 2011.

The biotech IPO market hasn't actually been a flatliner. The National Venture Capital Association reckons that at least eight U.S. biotech firms went public in 2010 and lists a dozen more already on Wall Street's runway this year.

Leading this would-be class of 2011 is Fluidigm, a South San Francisco firm that makes bio-chips to automate and expedite the processing of biological samples. Fluidigm tried to go public in September 2008 - just as the financial crisis nearly brought down the world economy. Now its born-again bid will be among the first signals of public investor sentiment in the new year.

Read more: http://www.sfgate.com/cgi-bin/article.cgi?f=/c/a/2011/01/10/BUDQ1H70VU.D...

The investors will break-even at best after a decade of waiting. the company is desperate for cash and still in the red. IPO now or close the doors. The CEO also sells swamp land on the side. Any buyers? maybe only the last poster.

Fluidigm Corp., a South San Francisco company that makes microfluidic systems for the life science and agricultural biotech markets, filed paperwork Friday for an $86.25 million initial public offering.
It’s the second IPO filing by the company, which in fall 2008 withdrew a $74.2 million offering as the financial markets sagged and investors fled. Still, Fluidigm CEO Gajus Worthington told me a year ago that he was convinced that the 175-employee company had a compelling story to tell about its chips, which are used in genetic analysis, when the markets opened up again.
See Fluidigm’s S-1 filing with the Securities and Exchange Commission here.

This is a re-occuring theme for Fluidgm: A new hopeful product that should sell well and then doesn't. The re-usable chip is just another loser in a long string of losers for poor Fluidigm. Their current great hope is the access array. How is that product doing?

Fluidigms reuseable IFC products. Fluidigm appears to have abandoned the reuseable product line due to a lack of customer support and tech issues. no longer offered through the website and also not a surprise. Customers were supposed to gobble it up.